Homozygous glucagon-GFP knock-in mice (Gcggfp/gfp) lack proglucagon derived-peptides including glucagon and GLP-1, and are normoglycemic. We have previously shown that Gcggfp/gfp show improved glucose tolerance with enhanced insulin secretion. Here, we studied glucose and energy metabolism in Gcggfp/gfp mice fed a high-fat diet (HFD). Male Gcggfp/gfp and Gcggfp/+ mice were fed either a normal chow diet (NCD) or an HFD for 15–20 weeks. Regardless of the genotype, mice on an HFD showed glucose intolerance, and Gcggfp/gfp mice on HFD exhibited impaired insulin secretion whereas Gcggfp/+ mice on HFD exhibited increased insulin secretion. A compensatory increase in β-cell mass was observed in Gcggfp/+mice on HFD, but not in Gcggfp/gfp mice on the same diet. Weight gain was significantly lower in Gcggfp/gfp mice than in Gcggfp/+mice. Oxygen consumption was enhanced in Gcggfp/gfp mice compared to Gcggfp/+ mice on an HFD. HFD feeding significantly increased uncoupling protein 1 mRNA expression in brown adipose and inguinal white adipose tissues of Gcggfp/gfp mice, but not of Gcggfp/+mice. Treatment with the glucagon-like peptide-1 receptor agonist liraglutide (200 mg/kg) improved glucose tolerance in Gcggfp/gfp mice and insulin content in Gcggfp/gfp and Gcggfp/+ mice was similar after liraglutide treatment. Our findings demonstrate that Gcggfp/gfp mice develop diabetes upon HFD-feeding in the absence of proglucagon-derived peptides, although they are resistant to diet-induced obesity.
Citation: Takagi Y, Kinoshita K, Ozaki N, Seino Y, Murata Y, Oshida Y, et al. (2015) Mice Deficient in Proglucagon-Derived Peptides Exhibit Glucose Intolerance on a High-Fat Diet but Are Resistant to Obesity. PLoS ONE 10(9): e0138322. https://doi.org/10.1371/journal.pone.0138322
Editor: Julie A. Chowen, Hosptial Infantil Universitario Niño Jesús, CIBEROBN, SPAIN
Received: April 23, 2015; Accepted: August 28, 2015; Published: September 17, 2015
Copyright: © 2015 Takagi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This work was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (22590974 to NO and 24659451 to YH), and by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology (23122507 and 25122708 to YH).
Competing interests: The authors have declared that no competing interests exist.
Diabetes mellitus is characterized by chronic hyperglycemia, and is often associated with obesity. Glucagon, a counter-regulatory hormone to insulin, is one of the most important regulators of glucose homeostasis. It has been recognized that the concerted actions of insulin and glucagon keep plasma glucose levels normal, and that any imbalance in the actions of these molecules can contribute to an increased demand for insulin, impaired glucose tolerance, and persistent hyperglycemia in type 2 diabetes . Under normal physiological conditions, serum glucagon concentration immediately decreases after a meal, whereas in subjects with type 2 diabetes, it can even be found to be elevated after a meal [2–4]. It has therefore been recognized that inappropriate glucagon secretion is at least in part responsible for the pathophysiology of diabetes mellitus [5, 6].
The main physiological role of glucagon is to stimulate hepatic glucose output in order to maintain glucose homeostasis . The physiological role of glucagon in glucose homeostasis has been investigated in animal models where glucagon signaling was blocked at the receptor level by either genetic or pharmacological means: Glucagon receptor knockout mice (Gcgr-/- mice) had lowered plasma glucose levels without exhibiting hypoglycemia [8, 9], whereas treating the animals with glucagon receptor antagonists reduced blood glucose levels in various rodent models [10, 11]. Furthermore, the role of glucagon has been investigated in the pathophysiology of metabolic disorders, where absence of glucagon action was shown to ameliorate diet-induced obesity and diabetes. For example, pharmacological blockage of glucagon receptor signaling was shown to improve glucose metabolism in animals that were fed a high-fat diet (HFD) . Similarly, Gcgr-/- mice were found to be resistant to HFD-induced obesity because of reduced energy intake . However, both glucagon and glucagon-like peptide-1 (GLP-1) are derived from a common precursor, proglucagon, and these animals exhibited elevated levels of circulating glucagon-like peptide-1 (GLP-1) as a consequence to compensate glucagon deficiency. Therefore, the role of glucagon and GLP-1 and their contribution to the pathophysiology of diabetes and obesity remain to be fully clarified.
Obesity is now recognized as a major epidemic and is associated with diseases such as metabolic syndrome, type 2 diabetes mellitus, and atherosclerotic cardiovascular disease . Disturbing the balance between energy intake and energy expenditure plays a crucial role in the pathogenesis of obesity. The capacity for increased thermogenesis through brown adipose tissue (BAT) activation is important for body weight homeostasis . In addition, the development of inducible brown-like adipocytes (also referred to as “brite” or “beige” adipocytes), in white adipose tissue (WAT) depots in response to certain stimuli has recently been reported, suggesting that these adipocytes have the potential to tilt the energy balance from storage to expenditure . In response to various physiological and pharmacological stimuli, the expression of brown-fat-like genes such as uncoupling protein 1 (Ucp1), cell death-inducing DFFA-like effector a (Cidea) and deiodinase iodothyronine type II (Dio2) are induced in WAT. These changes in expression patterns contribute to adaptive thermogenesis and energy expenditure similar to those seen in classical BAT . Glucagon is also involved in the control of energy expenditure and thermogenesis [17, 18].
We recently reported that homozygous glucagon-GFP knock-in mice (Gcggfp/gfp), which lack not only glucagon but also GLP-1 and GLP-2, are normoglycemic and display improved glucose tolerance with enhanced insulin secretion upon acute glucose loading [19, 20]. Gcggfp/gfp mice exhibited cold intolerance and impaired thermogenesis in response to a cold stimulus . To further understand the roles of proglucagon-derived peptides (PGDPs) in the pathophysiology of obesity and diabetes, we examined glucose and energy metabolism in Gcggfp/gfp mice fed HFD.
This study was performed according to a protocol approved by the Nagoya University Institutional Animal Care and Use Committee. The establishment of the glucagon-GFP knock-in mice backcrossed with C57BL/6J background for at least 12 generations have been previously described . The mice were housed in a temperature-controlled room under a standard 12-h light/dark cycle. Five-week-old Gcggfp/gfp and Gcggfp/+male mice were divided into two groups and fed either a normal chow diet (NCD, 12.6% energy content of fat; CE-2 from CLEA Japan, Osaka, Japan) or a high-fat diet (HFD, 56.7% energy content of fat; HFD32 from CLEA Japan) for 15–20 weeks. For GLP-1 supplementation experiments, GLP-1 receptor agonist liraglutide (200 mg/kg) was subcutaneously administered once daily during the final 4 weeks of HFD-feeding. Tissue samples were collected from mice that were fasted for 16 h or from mice that were fed for 6 h after a 16-h starvation period. Gcggfp/+ mice were used as control in the present study, as Gcggfp/+ and Gcg+/+ mice do not differ in terms of glucose tolerance and hepatic gene expression patterns [19, 20, 22, 23].
Glucose tolerance test and insulin tolerance test
These tests were performed on mice that were fed a NCD or an HFD for 15 weeks, as described previously . In brief, mice were deprived of food for 16 h, and 2 g/kg body weight of glucose was intraperitoneally administered (IPGTT). IPGTT in liraglutide-treated mice was performed after treatment for 2 weeks. For insulin tolerance test (ITT), five hours after food depletion and immediately before the experiments were carried out insulin was injected at a dose of 0.75 U/kg. Blood was collected at multiple time intervals to measure glucose and insulin levels by subzygomatic approach using goldenrod animal lancet. Alternatively, tale tip bleeding was also employed when only glucose level was measured.
Islet isolation, measurement of insulin, and morphometric analysis
Pancreatic islets were isolated using the collagenase digestion method and glucose-induced insulin secretion from isolated islets were carried out as described previously . Briefly, sets of 5 islets similar in size were hand-picked from pooled isolated islets and incubated in the Krebs-Ringer buffer containing 2.8 mmol/L glucose for 30 min, groups of five islets were incubated in the Krebs-Ringer buffer containing 16.7 mmol/L glucose for 30 min. Insulin concentration in the buffer was analyzed and normalized to cellular insulin content. Immunohistochemistry and morphometric analysis were performed as described previously . Briefly, the pancreata were fixed in 4% paraformaldehyde and embedded in paraffin. Tissue sections were incubated overnight at 4°C with primary antibodies against insulin (1:1000; Abcam plc, Cambridge, UK) or Ki-67 (1:250; Abcam) followed by a 90-min incubation with Alexa Fluor-conjugated secondary antibody (1:500; Alexa Fluor 488 or 1:1000, Alexa Fluor 568, Invitrogen, Grand Island, NY, USA) at room temperature. Images were taken using an HS BZ-9000 fluorescence microscope system (Keyence Corp., Osaka, Japan). For morphometric analyses, serial sections of 4–5 μm thickness were cut from each paraffin block at 200-μm intervals, and 4–5 sections were randomly selected from each mouse and immunostained for insulin and Ki-67. The insulin-positive cell areas relative to the sectional area or the number of Ki-67-positive cells relative to insulin-positive islet cells (3890±540 cells per mouse) were determined by the HS BZ-II analysis application and Image J software.
Determination of BAT triglyceride content and histological analysis in BAT
BAT triglyceride content was measured as previously described . The BAT was fixed in 4% paraformaldehyde, and then embedded in paraffin. 4 μm sections were stained with hematoxylin andeosin (H&E staining). Representative images of H&E stained sections were captured using an Olympus BX53 system (Olympus Corporation, Tokyo, Japan).
Blood glucose levels were measured with Antisense III (Horiba Ltd., Kyoto, Japan). Plasma insulin levels were determined using a mouse insulin enzyme-linked immunosorbent assay kit (Morinaga-Seikagaku Co. Ltd., Yokohama, Japan). Insulin in the medium and its content was determined using the HTRF insulin assay kit (Cisbio Bioassays, Bagnols-sur-Cèze, France).
A comprehensive animal metabolic monitoring system (CLAMS; Columbus Instruments, Columbus, OH, USA) was used for 3 days. Energy expenditure and respiratory exchange ratios (RER) were calculated by measuring gas exchange rates. The respiratory exchange ratio was computed as carbon dioxide output (VCO2) divided by oxygen consumption (VO2). Physical activity was measured on the x axes by counting the number of brakes in an infrared beam during a measurement period.
Isolation of tissue RNA and quantitative real-time RT-PCR
Total RNA was extracted from isolated islets, BAT and iWAT using RNAiso Plus reagent (Takara Bio Inc., Shiga, Japan) or the RNeasy Plus Kit (Qiagen Inc., Valencia, CA, USA). Complementary DNA was synthesized using a PrimeScript RT Master Mix (Takara Bio Inc.). Quantitative real-time RT-PCR was performed with the StepOne real-time PCR Systems (Applied Biosystems, Foster City, CA, USA) by using a THUNDERBIRD SYBR qPCR Mix (TOYOBO Co. Ltd, Osaka, Japan). The sequences of the primers used for the analyses are available upon request.
Data are presented as means ± SEM. Significance was evaluated using Student’s t test or ANOVA followed by post-test comparisons when applicable. Energy expenditure was analyzed by using ANCOVA with body weight as the covariate. A p value < 0.05 was regarded as statistically significant.
Gcggfp/gfp and Gcggfp/+ mice were fed a NCD or an HFD for 15 weeks beginning at 5 weeks after birth. While decreases in blood glucose levels in response to insulin administration was impaired in both mice on an HFD (NCD vs HFD in both Gcggfp/+ and Gcggfp/gfp: p<0.05 at 0, 30, 60 and 90 min after insulin administration), Gcggfp/gfp mice exhibited lower glucose levels compared to Gcggfp/+ mice, indicating that insulin resistance in Gcggfp/gfp mice was much less severe than in Gcggfp/+ mice (Fig 1A). Glucose tolerance, evaluated by IPGTT, was markedly impaired in both Gcggfp/+ and Gcggfp/gfp mice on HFD (Fig 1B). In mice fed NCD, blood glucose levels in Gcggfp/gfp was significantly lower compared to Gcggfp/+ at 30 and 60 minutes after glucose load. However, in mice fed HFD, no significant difference in blood glucose levels were observed between Gcggfp/+ and Gcggfp/gfp at the same time points. Plasma insulin levels measured at 0 and 15 min after glucose loading were significantly increased in Gcggfp/+ mice on HFD compared to those on NCD, whereas such increase was not observed in Gcggfp/gfp mice (Fig 1C). We further examined glucose-induced insulin secretion from isolated islets of HFD-fed mice, finding it to be significantly reduced in Gcggfp/gfp mice in comparison with Gcggfp/+ mice (Fig 1D). These results suggest that HFD-induced changes in β-cell function are attenuated in Gcggfp/gfp mice deficient in PGDPs.
(A) Insulin tolerance test. Open circles, Gcggfp/+ mice; closed circles, Gcggfp/gfp mice (n = 5–7). *p < 0.05; **p < 0.01. (B) Blood glucose levels during IPGTT. Open circles, Gcggfp/+ mice; closed circles, Gcggfp/gfp mice (n = 4–6). *p < 0.05; **p < 0.01; ***p < 0.001. (C) Plasma insulin levels at 0 min (white bars) and 15 min (black bars) after i.p. glucose loading (n = 4–6). **p < 0.01; ***p < 0.001. (D) Glucose-induced insulin secretion from isolated islets. Isolated islets were stimulated by 2.8 mmol/L glucose (white bars) or 16.7 mmol/L glucose (black bars) for 30 min. Insulin secretion is expressed as the ratio of insulin released into the medium relative to insulin content (n = 6–12). ***p < 0.001. Data are presented as means ± SEM.
To clarify the cause for impaired insulin secretion in Gcggfp/gfp mice, we analyzed the morphology of pancreatic islets and their gene expression. Morphometric analysis revealed that HFD-feeding increased β-cell area in Gcggfp/+ mice, but failed to increase β-cell area in Gcggfp/gfp mice (Fig 2A and S1 Fig). Pancreas weight and β-cell mass are shown in S2 and S3 Figs, and these data showed that no significant increase in β-cell mass was induced by HFD-feeding in Gcggfp/gfp mice. In addition, HFD-feeding resulted in a 2-fold increase of insulin content in pancreata of Gcggfp/+ mice, whereas this increase was diminished in Gcggfp/gfp mice (Fig 2B). We performed immunostaining for Ki-67 to estimate β-cell proliferation, and observed an increase in Ki-67-positive β-cells in Gcggfp/+ mice on an HFD, but not in Gcggfp/gfp mice on the same diet (Fig 2C). Expression of the pancreatic duodenal homeobox-1 (Pdx1) gene, which is an important transcription factor for β-cell proliferation and survival, was up-regulated in islets of Gcggfp/+ mice on an HFD. By contrast, up-regulation of Pdx1 expression by HFD-feeding was not observed in islets of Gcggfp/gfp mice (Fig 2D). Expression of cyclin D2 and insulin receptor substrate-2 (Irs2) did not change significantly by HFD-feeding (Fig 2D).
(A) β-cell area is shown as insulin-positive area relative to total pancreas area by morphometric analysis (n = 5–6). (B) Insulin contents in pancreata (n = 6–9). (C) Proliferation of pancreatic β-cells. Percentage of Ki-67-positive β-cells is shown as the number of Ki-67-positive cells relative to insulin-positive islet cells. White bars, mice fed NCD; black bars, mice fed HFD (n = 3–4). **p < 0.01. (D) mRNA Expression of Irs2, Pdx1, and cyclin D2 in islets. White bars, mice fed NCD; black bars, mice fed HFD (n = 4–8). *p < 0.05; **p < 0.01. Data are presented as means ± SEM.
Body weight and energy metabolism
Although both Gcggfp/gfp and Gcggfp/+ mice on HFD showed an increase in body weight throughout the experimental period, the ratio of weight gain in Gcggfp/gfp mice was lower than in Gcggfp/gfp mice (46.7% vs. 20.1%, Fig 3A). S4 Fig depicts difference in body weight between mice fed NCD and those fed HFD. Body weight gain of Gcggfp/+ mice at 15 weeks of HFD-feeding was greater than that of Gcggfp/gfp mice (Fig 3B). In concordance with our previous study , under NCD-feeding, both mice showed comparable levels of energy intake, physical activity, VO2, VCO2 and RER (Fig 3C-3E). However, Gcggfp/gfp mice on HFD exhibited higher levels of VO2, VCO2 and RER compared to Gcggfp/+ mice on the same diet (Fig 3C-3E). Although energy intake was suppressed in HFD-fed mice relative to the NCD-fed mice, under HFD-feeding, energy intake in Gcggfp/gfp mice was significantly higher than in Gcggfp/+ mice (Fig 3F). These results in addition to the observation that HFD-feeding did not alter physical activity in either mice (Fig 3G), indicate that Gcggfp/gfp mice retained normal energy expenditure even under HFD-feeding.
(A) Body weight changes during HFD feeding. (B) Body weight gain at 15 weeks of HFD-feeding. (C) Oxygen consumption (VO2). (D) Carbon dioxide output (VCO2). (E) Respiratory exchange rates (RER). (F) Energy intake. (G) Physical activity. White bars, mice fed NCD; black bars, mice fed HFD (n = 6–8). *p < 0.05; **p < 0.01; ***p < 0.001. Data are presented as means ± SEM.
Analysis of adipose tissue
Given the crucial role of BAT in energy expenditure, we next analyzed histology and gene expression in intrascapular BAT. BAT weight in Gcggfp/gfp mice did not increase by HFD-feeding, whereas HFD-feeding increased BAT weight in Gcggfp/+ mice (Fig 4A). Histological analysis revealed smaller fat droplets and significantly lower triglyceride content in BAT of Gcggfp/gfp mice on HFD than in that of Gcggfp/+ mice on the same diet (Fig 4B and 4C). Under NCD-feeding, Ucp1 mRNA expression in Gcggfp/gfp BAT was significantly lower than that in Gcggfp/+ BAT, while Dio2 mRNA expression was comparable between the both mice (Fig 4D). By contrast, HFD-feeding induced a significant increase in Ucp1 and Dio2 mRNA only in BAT of Gcggfp/gfp mice (Fig 4D). These results indicate that accumulation of lipid in BAT induced by HFD-feeding was attenuated in Gcggfp/gfp mice and that expenditure of lipids as an energy source was increased in the BAT of Gcggfp/gfp mice on HFD.
(A) Intrascapular BAT weights after NCD- or HFD-feeding (n = 6–8). (B) Representative H&E staining of BAT. (C) Triglyceride contents in BAT (n = 4). (D) mRNA expression of Ucp1, Ppargc1a, and Dio2 in BAT (n = 5–8). (E) mRNA expression of Ucp1, Ppargc1a, Dio2, F4/80, Mcp1, Tnfa, Tbx1, Cd137, and Cidea in inguinal WAT. White bars, mice fed on a NCD; black bars, mice fed on an HF diet (n = 4–5). *p < 0.05; ***p < 0.001. Data are presented as means ± SEM.
We also examined gene expression in inguinal white adipose tissue (iWAT) because brown-like adipocytes have the potential to tilt the energy balance from storage to expenditure . We found that HFD-feeding induced mRNA expression of Ucp1, and Ppargc1a, but not Cidea (the classical BAT marker), in iWAT (Fig 4E). In addition, HFD-feeding induced the expression of Tbx1 and Cd137 (molecular markers of brown-like adipocytes) in Gcggfp/gfp mice but not in Gcggfp/+ mice. These results indicate that HFD-feeding differentially alters gene expression in iWAT. On the other hand, expression of F4/80 and Mcp-1 was induced by HFD feeding in Gcggfp/+ mice but not in Gcggfp/gfp mice, suggesting macrophages infiltration in Gcggfp/+. These results suggest that, similar to BAT, energy expenditure in iWAT is also enhanced in Gcggfp/gfp mice.
Treatment with GLP-1 receptor agonist liraglutide
GLP-1 is known to stimulate not only insulin secretion but also β-cell proliferation both in vivo and in vitro . To clarify whether the absence of GLP-1 is responsible for impaired β-cell function in Gcggfp/gfp mice, effect of GLP-1 receptor agonist liraglutide administration at 200 μg/kg, once daily during the last 4 weeks of HFD-feeding, was analyzed. Treatment with liraglutide significantly reduced body weights in both Gcggfp/+ and Gcggfp/gfp mice on an HFD (Fig 5A). The peak blood glucose levels during IPGTT were 32.1±1.6 and 32.1±1.9 in liraglutide-treated Gcggfp/+ and Gcggfp/gfp mice, respectively (Fig 5B). As those in HFD-fed Gcggfp/+ and Gcggfp/gfp mice were 47.1±1.7 and 46.8±1.9 respectively (see Fig 1B), liraglutide significantly improved glucose tolerance in these mice (p<0.001 and <0.001 in Gcggfp/+ and Gcggfp/gfp, respectively). Furthermore, blood glucose levels in liraglutide-treated Gcggfp/+ mice were significantly lower than liraglutide-treated Gcggfp/gfp mice at time points later than 60 min after glucose administration (Fig 5B). These results suggest that Gcggfp/gfp mice are more responsive to GLP-1 administration than the control mice. Although no significant increase in plasma insulin levels to glucose load was observed in liraglutide-treated, HFD-fed Gcggfp/gfp (Fig 5C), insulin content in these animals was 230.0±21.1 μg/g tissue, which was significantly greater (p< 0.01) than 118.3 ±12.3 μg/g tissue in HFD-fed Gcggfp/gfp mice (Figs 2B and 5D). Collectively, GLP-1 agonist markedly ameliorated metabolic changes caused by HFD-feeding in the Gcggfp/gfp mice.
(A) body weights during liraglutide treatment (n = 6–7). Open circles, liraglutide-treated Gcggfp/+ mice on HFD; closed circles, liraglutide-treated Gcggfp/gfp mice on HFD. **p < 0.01 vs Gcggfp/+ mice. #p < 0.05; ##p < 0.01 vs. before liraglutide treatment. (B) Blood glucose levels during IPGTT (n = 6–7). Open circles, liraglutide-treated Gcggfp/+ mice on HFD; closed circles, liraglutide-treated Gcggfp/gfp mice on HFD. *p < 0.05; ***p < 0.001 vs. Gcggfp/+ mice. (C) Plasma insulin levels 0 min (white bars) and 15 min (black bars) after i.p. glucose loading (n = 6–7). (D) Insulin contents in pancreata. White bars, liraglutide-treated Gcggfp/+ mice on HFD; black bars, liraglutide-treated Gcggfp/gfp mice on HFD (n = 5–7). Data are presented as means ± SEM.
Compared to insulin, glucagon has long been dismissed as a minor contributor to diabetes. However, it was recently reported that destruction of β-cells by treatment with streptozotocin in Gcgr-/- mice failed to increase blood glucose levels . Glucagonocentrism was proposed as a new framework to facilitate such results whereby a lack of insulin was proposed to lead to glucagon excess, in turn causing diabetes abnormalities . In the present study, we showed that in spite of a glucagon deficiency, HFD-fed Gcggfp/gfp mice did develop diabetes, which was due to impaired insulin secretion and not insulin resistance. Our results thus indicate that glucagon is not essential for pathogenesis of HFD-induced diabetes and that secondary increases in GLP-1 should play roles in resistance to develop diabetes in other glucagon-deficient models.
Under an insulin-resistant or hyperglycemic condition, β-cell compensates for an increased insulin demand by increasing its capacity for secretion and by expanding its mass [28, 29]. In the present study, we found that such compensation is defective in Gcggfp/gfp mice fed HFD; no increase in capacity of insulin secretion nor any β-cell expansion was observed in these mice. In contrast to Gcggfp/gfp mice, Gcgr-/- mice showed improved glucose tolerance upon oral GTT and IPGTT treatment, when compared with wild type mice on HFD . It has also been shown that administration of glucagon receptor antagonist for 24–30 days to mice on HFD enhances insulin secretion, increases β-cell mass, and improves glucose tolerance . Except for Gcggfp/gfp mice, these glucagon-deficient models exhibits increased GLP-1 levels in circulation [13, 30]. GLP-1 is known to stimulate not only insulin secretion but also β-cell expansion by acting as a growth factor both in experimental animal models as well as cultured β-cells, promoting their proliferation, survival, and differentiation . Therefore absence of GLP-1 in Gcggfp/gfp mice should account for defective β-cell compensation.
Indeed, Glp1r-/- mice fed HFD exhibited no significant increase in pancreatic insulin content and β-cell mass . Jun et al recently demonstrated that loss of GLP-1 action aggravates glucose tolerance in mice deficient in glucagon receptor . In addition, restoration of islet GLP-1 receptor expression enhanced exendin-4-induced β-cell proliferation and expansion of β-cell mass in Glp1r-/- mice on HFD . Thus, the findings in models with antagonized glucagon action can be explained by elevated GLP-1 levels in circulation. Omar et al. recently reported that treatment with GLP-1 receptor antagonist Exendin 9–39 in streptozotocin-treated Gcgr-/- mice significantly increased the glycemic excursion during OGTT . It is in this context that we assumed that administration of GLP-1 receptor agonist liraglutide should improve β-cell function in Gcggfp/gfp mice on an HFD. Indeed, liraglutide treatment for 4 weeks enhanced insulin secretion and pancreatic insulin content in HFD-fed Gcggfp/gfp mice. These results therefore indicate that GLP-1 deficiency contributes to the failure of β-cell compensation in the face of increased insulin demand.
In the present study, Gcggfp/gfp mice fed HFD showed resistance to diet-induced obesity. Energy expenditure in Gcggfp/gfp mice fed HFD was higher than that in Gcggfp/+ mice on an HFD, and expression of Ucp1 and Dio2 were markedly increased in the BAT of Gcggfp/gfp mice on the HFD. These results suggest that proglucagon-derived peptides promote diet-induced obesity through unknown mechanisms. The exact role of proglucagon-derived peptides in diet-induced obesity is still poorly understood. Previous studies on the effect of exogenous glucagon administration on energy expenditure have suggested that glucagon has beneficial effects on the regulation of body weight and energy expenditure [17, 18]. We have also recently reported that endogenous glucagon is essential for adaptive thermogenesis . Furthermore, HFD-induced body weight gain in Gcgr-/- mice was lower than control mice due to the reduction of energy intake . Although several line of evidence suggests that GLP-1 plays some roles in resistance to diet-induced obesity, Glp1r-/- mice exhibited resistance to diet-induced obesity due to enhanced physical activity and increased energy expenditure [35, 36]. Studies using administration of GLP-1 agonists and/or antagonists have also provided controversial results on the role of GLP-1 in energy expenditure [37–40]. Our findings, therefore, provide a possibility that combined action of PGDPs is involved in diet-induced obesity via the suppression of BAT activity.
We showed that HFD-feeding induced browning of iWAT in Gcggfp/gfp mice but not in Gcggfp/+ mice, and that inflammation of iWAT in Gcggfp/gfp mice was much less severe than in Gcggfp/+ mice. Brown-like adipocytes develop in WAT in response to cold exposure or β-adrenergic stimulation . While induction of browning of WAT by HFD, has not been widely recognized, it was recently reported that prolactin deficient mice exhibit brite adipocytes development in perirenal WAT upon HFD-feeding . The mechanisms underlying the induction of iWAT browning under HFD-feeding remain unknown. Recently, Sakamoto et al. reported that inflammation induced by RAW macrophages suppresses Ucp1 mRNA induction in 10T1/2 adipocytes . Our results therefore suggest that the depletion of proglucagon-derived peptides suppresses the inflammation in iWAT, thereby inducing browning of WAT under HFD-feeding.
In the present study, we showed that mice deficient in proglucagon-derived peptides are resistant to diet-induced obesity but develop diabetes mellitus due to defective β-cell compensation, indicating that glucagon is not a prerequisite for development of diet-induced diabetes. Furthermore, our results demonstrate that GLP-1 is responsible for β-cell compensation triggered by increased insulin demand. Intriguingly, the absence of PGDPs appears to play a pivotal role in facilitating resistance to diet-induced obesity, increased energy expenditure, conserved BAT function, and browning of inguinal WAT. Here, we have unveiled novel aspects of the physiological action of PGDPs, particularly in the functional regulation of adipose tissue.
S1 Fig. Representative section from Gcggfp/+ (upper) and Gcggfp/gfp (lower) mice.
Sections were immunostained for insulin (red) and shown with autofluororescence of GFP (green). NCD, mice fed a normal-chow diet; HFD, mice fed a high-fat-diet.
S2 Fig. Pancreatic weight.
(A) Pancreatic weight (B) Pancreatic weight is shown as pancreatic weight relative to body weight (BW). White bars, mice fed NCD; black bars, mice fed HFD (n = 5–6). *p < 0.05; ***p < 0.001. Data are presented as means ± SEM.
S3 Fig. β-cell mass (%).
β-cell mass (mg) is shown as β-cell area (%) multiplied by pancreatic weight. White bars, mice fed NCD; black bars, mice fed HFD (n = 5–6). ***p < 0.001. Data are presented as means ± SEM.
S4 Fig. Body weight gain on HFD.
ΔBW is shown as the difference of body weight (BW) between mice on NCD and mice on HFD at each time point. Open circles, Gcggfp/+ mice; closed circles, Gcggfp/gfp mice (n = 5–6). *p < 0.05; **p < 0.01; ***p < 0.001. Data are presented as means ± SEM.
Conceived and designed the experiments: YT KK NO YS YM YO YH. Performed the experiments: YT KK NO YH. Analyzed the data: YT KK NO YS YH. Contributed reagents/materials/analysis tools: YT KK NO YH. Wrote the paper: YT NO YH.
- 1. Li XC, Zhuo JL (2013) Current insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes. Curr Hypertens Rep 15: 522–530 pmid:23996678
- 2. Basu A, Alzaid A, Dinneen S, Caumo A, Cobelli C, Rizza RA (1996) Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J Clin Invest 97: 2351–2361 pmid:8636416
- 3. Butler PC, Rizza RA (1991) Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 40: 73–81 pmid:2015976
- 4. Larsson H, Ahren B (2000) Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care 23: 650–657 pmid:10834425
- 5. Baron AD, Schaeffer L, Shragg P, Kolterman OG (1987) Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36: 274–283 pmid:2879757
- 6. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA (2000) Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85: 4053–4059 pmid:11095432
- 7. Jiang G, Zhang BB (2003) Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284: E671–678 pmid:12626323
- 8. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, et al. (2003) Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100: 1438–1443 pmid:12552113
- 9. Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD (2002) Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 290: 839–843 pmid:11785978
- 10. Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D (1982) Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 215: 1115–1116 pmid:6278587
- 11. Van Tine BA, Azizeh BY, Trivedi D, Phelps JR, Houslay MD, Johnson DG, et al. (1996) Low level cyclic adenosine 3',5'-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists. Endocrinology 137: 3316–3322 pmid:8754757
- 12. Winzell MS, Brand CL, Wierup N, Sidelmann UG, Sundler F, Nishimura E, et al. (2007) Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet. Diabetologia 50: 1453–1462 pmid:17479245
- 13. Conarello SL, Jiang G, Mu J, Li Z, Woods J, Zycband E, et al. (2007) Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated β cell loss and hyperglycaemia. Diabetologia 50: 142–150 pmid:17131145
- 14. Chatzigeorgiou A, Kandaraki E, Papavassiliou AG, Koutsilieris M (2014) Peripheral targets in obesity treatment: a comprehensive update. Obes Rev
- 15. Lockie SH, Stefanidis A, Oldfield BJ, Perez-Tilve D (2013) Brown adipose tissue thermogenesis in the resistance to and reversal of obesity: A potential new mechanism contributing to the metabolic benefits of proglucagon-derived peptides. Adipocyte 2: 196–200 pmid:24052894
- 16. Lo KA, Sun L (2013) Turning WAT into BAT: a review on regulators controlling the browning of white adipocytes. Biosci Rep 33: e00065 pmid:23895241
- 17. Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschop MH (2010) The metabolic actions of glucagon revisited. Nat Rev Endocrinol 6: 689–697 pmid:20957001
- 18. Heppner KM, Habegger KM, Day J, Pfluger PT, Perez-Tilve D, Ward B, et al. (2010) Glucagon regulation of energy metabolism. Physiol Behav 100: 545–548 pmid:20381509
- 19. Fukami A, Seino Y, Ozaki N, Yamamoto M, Sugiyama C, Sakamoto-Miura E, et al. (2013) Ectopic expression of GIP in pancreatic β-cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides. Diabetes 62: 510–518 pmid:23099862
- 20. Hayashi Y, Yamamoto M, Mizoguchi H, Watanabe C, Ito R, Yamamoto S, et al. (2009) Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of islet α-cells but not of intestinal L-cells. Mol Endocrinol 23: 1990–1999 pmid:19819987
- 21. Kinoshita K, Ozaki N, Takagi Y, Murata Y, Oshida Y, Hayashi Y (2014) Glucagon is essential for adaptive thermogenesis in brown adipose tissue. Endocrinology 155: 3484–3492 pmid:24949663
- 22. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR (2011) Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 152: 3103–3112 pmid:21693680
- 23. Watanabe C, Seino Y, Miyahira H, Yamamoto M, Fukami A, Ozaki N, et al. (2012) Remodeling of hepatic metabolism and hyperaminoacidemia in mice deficient in proglucagon-derived peptides. Diabetes 61: 74–84 pmid:22187375
- 24. Sakamoto E, Seino Y, Fukami A, Mizutani N, Tsunekawa S, Ishikawa K, et al. (2012) Ingestion of a moderate high-sucrose diet results in glucose intolerance with reduced liver glucokinase activity and impaired glucagon-like peptide-1 secretion. J Diabetes Invest 3: 432–440
- 25. Buteau J (2008) GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival. Diabetes Metab 34 Suppl 2: S73–77 pmid:18640589
- 26. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH (2011) Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60: 391–397 pmid:21270251
- 27. Unger RH, Cherrington AD (2012) Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 122: 4–12 pmid:22214853
- 28. Prentki M, Nolan CJ (2006) Islet β cell failure in type 2 diabetes. J Clin Invest 116: 1802–1812 pmid:16823478
- 29. Sachdeva MM, Stoffers DA (2009) Minireview: Meeting the demand for insulin: molecular mechanisms of adaptive postnatal β-cell mass expansion. Mol Endocrinol 23: 747–758 pmid:19196831
- 30. Mu J, Jiang G, Brady E, Dallas-Yang Q, Liu F, Woods J, et al. (2011) Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe α cell hypertrophy in diet-induced obese mice. Diabetologia 54: 2381–2391 pmid:21695571
- 31. Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y, et al. (2007) Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 117: 143–152 pmid:17187081
- 32. Jun LS, Millican RL, Hawkins ED, Konkol DL, Showalter AD, Christe ME, et al. (2015) Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production. Diabetes 64: 819–827 pmid:25288673
- 33. Lamont BJ, Li Y, Kwan E, Brown TJ, Gaisano H, Drucker DJ (2012) Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J Clin Invest 122: 388–402 pmid:22182839
- 34. Omar BA, Andersen B, Hald J, Raun K, Nishimura E, Ahren B (2014) Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice. Diabetes 63: 101–110 pmid:24062250
- 35. Ayala JE, Bracy DP, James FD, Burmeister MA, Wasserman DH, Drucker DJ (2010) Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. Endocrinology 151: 4678–4687 pmid:20685876
- 36. Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, et al. (2004) Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53: 1326–1335 pmid:15111503
- 37. Abegg K, Schiesser M, Lutz TA, Bueter M (2013) Acute peripheral GLP-1 receptor agonism or antagonism does not alter energy expenditure in rats after Roux-en-Y gastric bypass. Physiol Behav 121: 70–78 pmid:23562866
- 38. Bradley DP, Kulstad R, Racine N, Shenker Y, Meredith M, Schoeller DA (2012) Alterations in energy balance following exenatide administration. Appl Physiol Nutr Metab 37: 893–899 pmid:22735035
- 39. Knauf C, Cani PD, Ait-Belgnaoui A, Benani A, Dray C, Cabou C, et al. (2008) Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 149: 4768–4777 pmid:18556349
- 40. Osaka T, Endo M, Yamakawa M, Inoue S (2005) Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides 26: 1623–1631 pmid:16112402
- 41. Peschechera A, Eckel J (2013) "Browning" of adipose tissue—regulation and therapeutic perspectives. Arch Physiol Biochem 119: 151–160 pmid:23721302
- 42. Auffret J, Viengchareun S, Carre N, Denis RG, Magnan C, Marie PY, et al. (2012) Beige differentiation of adipose depots in mice lacking prolactin receptor protects against high-fat-diet-induced obesity. FASEB J 26: 3728–3737 pmid:22637534
- 43. Sakamoto T, Takahashi N, Sawaragi Y, Naknukool S, Yu R, Goto T, et al. (2013) Inflammation induced by RAW macrophages suppresses UCP1 mRNA induction via ERK activation in 10T1/2 adipocytes. Am J Physiol Cell Physiol 304: C729–738 pmid:23302779